Re:The truth about ‘breakthrough’ drugs
by Toenex on Monday August 20, 2018 @02:49PM
(#17802678)
But in a bid to mitigate risk (from their shareholders) big pharma effectively outsources lots of compound discovery to biotechs. This has helped create a large pool of biotech startups that never intend to run a phase 1 study but instead prepare for acquisition upon promising preclinical.
[ Parent
| on HN ]
There are no comments on this comment yet.